Global Pyrimethamine Industry to 2030 – by Indication, Route of Administration, Distribution Channel and Region

0

Dublin, April 18, 2022 (GLOBE NEWSWIRE) — The “Pyrimethamine Market, By Indication, By Route Of Administration, By Distribution Channel, And By Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2030” report has been added to from ResearchAndMarkets.com offer.

Pyrimethamine is a drug used to treat protozoan infections. Pyrimethamine belongs to a class of medications called antiparasitics. It works by killing parasites. It is commonly used as an antimalarial (for the treatment and prevention of malaria), as well as to treat Toxoplasma gondii infections, and it is also used in combination with the antibiotic sulfa sulfadiazine for the treatment of people who are HIV positive for the virus of human immunodeficiency (HIV). . Toxoplasmosis is a serious, life-threatening and sometimes fatal infection.

The Centers for Disease Control and Prevention (CDC) has recognized toxoplasmosis as one of the five neglected parasitic infections. A large number of people are infected with toxoplasmosis; however, only a few patients will have serious complications. The routes of transmission of Toxoplasma gondii infection are food, contact with animals (cats), water, soil and others.

As pyrimethamine is resistant to many species of Plasmodium, it is usually given in conjunction with sulfonamides and folinic acid. Pyrimethamine has also been found to limit gene expression for superoxide dismutase 1, a protein associated with amyotrophic lateral sclerosis.

Market dynamics

The growing number of HIV patients globally is expected to drive the growth of the global pyrimethamine market over the forecast period. For example, according to the Global HIV Statistics Fact Sheet published by the Joint United Nations Program on HIV/AIDS (UNAIDS), in 2020, worldwide, 37.7 million (30.2 million- 45.1 million) people were living with HIV, of which 36.0 million (28.9 million-43.2 million) were adults, 1.7 million (1.2 million-2.2 million) were children aged 0-14 and 53% of all people living with HIV were women and girls.

Main characteristics of the study:

  • This report provides an in-depth analysis of the Global Pyrimethamine Market, Market Size (Million US$) and Compound Annual Growth Rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles leading players in the global Pyrimethamine market based on the following parameters: company highlights, portfolio types, key highlights, financial performance, and market strategies.
  • Key companies covered in this study are Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd. and Abcam
  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics.
  • The report on the global pyrimethamine market is aimed at various stakeholders of this industry, including investors, suppliers, product manufacturers, distributors, new entrants and financial analysts.
  • Stakeholders would have an ease in making decisions through various strategic matrices used to analyze the global Pyrimethamine market

Main topics covered:

1. Research objectives and hypotheses

2. Competence of the market

  • Description of the report
  • Market definition and scope
  • Summary
  • Market overview, by indication
  • Market Snapshot, By Administration
  • Market overview, by distribution channel
  • Market Overview, By Region
  • Market Opportunity Map

3. Global Pyrimethamine Market Overview

  • Drivers
  • Constraints
  • Opportunity
  • Impact analysis
  • Pipeline analysis
  • Industry trends
  • New product launches
  • Key development
  • Regulatory scenario
  • Collaborations & Acquisitions
  • Epidemiology
  • PEST analysis
  • Porter’s Five Forces Analysis

4. Global Pyrimethamine Market- Impact of the Coronavirus (Covid-19) Pandemic

  • Economic impact
  • COVID-19 Epidemiology
  • Impact of COVID-19 on demand and supply chain

5. Global Pyrimethamine Market, By Indication, 2017-2030 (USD Million)

  • Introduction
  • Market share analysis, 2022 and 2030 (%)
  • Annual Growth Analysis, 2018 – 2030
  • Industry trends
  • Toxoplasmosis
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030 (USD Million)
  • Malaria
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030 (USD Million)
  • Others
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030 (USD Million)

6. Global Pyrimethamine Market, By Administration, 2017-2030 (USD Million)

  • Introduction
  • Market share analysis, 2022 and 2030 (%)
  • Annual Growth Analysis, 2018 – 2030
  • Industry trends
  • Parenteral
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030 (USD Million)
  • Oral
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030 (USD Million)

7. Global Pyrimethamine Market, By Distribution Channel, 2017-2030 (USD Million)

  • Introduction
  • Market share analysis, 2022 and 2030 (%)
  • Annual Growth Analysis, 2018 – 2030
  • Industry trends
  • Hospital pharmacies
  • Introduction
  • Market Size & Forecast & Annual Growth, 2017-2030, (USD Million)
  • Retail pharmacies
  • Introduction
  • Market Size & Forecast & Annual Growth, 2017-2030, (USD Million)
  • Online pharmacies
  • Introduction
  • Market Size & Forecast & Annual Growth, 2017-2030, (USD Million)

8. Global Pyrimethamine Market, by Region, 2017-2030 (USD Million)

9. Company Profiles

  • Vyera Pharmaceuticals, LLC.
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Cerovène Healthcare PVT. LTD
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • GlaxoSmithKline plc
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Impax Laboratories, Inc.
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • NCBO Bioportal
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Pfizer, Inc.
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Pharmaceutical PRN
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • SUDA Pharmaceuticals
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Taj Accura Pharmaceuticals
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • TargetMo Chemicals Inc.
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Evaluate Ltd.
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies
  • Abcam
  • Company Highlights
  • Product portfolio
  • Highlights
  • Financial performance
  • Strategies

10. Branch

For more information on this report, visit https://www.researchandmarkets.com/r/77i2jy

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Share.

Comments are closed.